Association Analysis between (AAT)n Repeats in the Cannabinoid Receptor 1 Gene and Schizophrenia in a Korean Population

한국인에서 조현병과 Cannabinoid Receptor 1 유전자의 삼핵산 반복서열의 연합에 대한 연구

  • Kim, Ji-Won (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Roh, Yang-Ho (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Kim, Min-Jea (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Kim, Chea-Ri (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Park, Byung-Lae (Department of Genetic Epidemiology, SNP Genetics, Inc.) ;
  • Bae, Joon Seol (Laboratory of Translational Genomics, Samsung Genome Institute, Samsung Medical Center) ;
  • Shin, Hyoung Doo (Department of Life Science, Sogang University) ;
  • Choi, Ihn-Geun (Department of Neuropsychiatry, Kangnam Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Han, Sang-Woo (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Hwang, Jaeuk (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University) ;
  • Woo, Sung-Il (Department of Psychiatry, Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University)
  • 김지원 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 노양호 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 김민재 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 김채리 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 박병래 ((주)에스엔피 제네틱스 유전역학부) ;
  • 배준설 (삼성의료원 삼성유전체연구소 유전체의학연구실) ;
  • 신형두 (서강대학교 생명공학과) ;
  • 최인근 (한림대학교 의과대학 강남성심병원 정신건강의학교실) ;
  • 한상우 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 황재욱 (순천향대학교 의과대학 서울병원 정신건강의학교실) ;
  • 우성일 (순천향대학교 의과대학 서울병원 정신건강의학교실)
  • Received : 2014.06.12
  • Accepted : 2014.07.24
  • Published : 2014.08.28

Abstract

Objectives Previous studies suggest that the cannabinoid receptor 1 (CNR1) gene could be an important candidate gene for schizophrenia. According to linkage studies, this gene is located on chromosome 6q14-q15, which is known to harbor the schizophrenia susceptibility locus (locus 5, SCZ5, OMIM 803175). The pharmacological agent delta-9-tetrahydrocannabinol (${\Delta}$-9-THC) seems to elicit the symptoms of schizophrenia. The association between CNR1 polymorphisms and schizophrenia is actively being investigated, and some studies have linked the AAT-trinucleotide repeats in CNR1 to the onset of schizophrenia. In this study, we have investigated the association between the AAT-trinucleotide repeats in CNR1 and schizophrenia by studying schizophrenia patients and healthy individuals from Korea. Methods DNA was extracted from the blood samples of 394 control subjects and 337 patients diagnosed with schizophrenia (as per the Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria). After polymerase chain reaction amplification, a logistic regression analysis, with age and gender as the covariates, was performed to study the variations in the AAT-repeat polymorphisms between the two groups. Results In total, 8 types of trinucleotide repeats were identified, each containing 7, 8, 10, 11, 12, 13, 14, and 15 repeats, respectively. $(AAT)_{13}$ allele was most frequently observed, with a frequency of 33.6% and 31.6% in the patient and control groups, respectively. The frequency of the other repeat alleles in the patient group (in the decreasing order) was as follows : $(AAT)_{13}$ 33.6%, $(AAT)_{14}$ 21.6%, $(AAT)_{12}$ 18.5%, and $(AAT)_{7}$ 11.1%. The frequency of the repeat alleles in the control group (in the decreasing order) was as follows : $(AAT)_{13}$ 31.6%, $(AAT)_{14}$ 24.5%, $(AAT)_{12}$ 17.2%, and $(AAT)_{7}$ 11.6%. However, there were no significant differences in the AAT-repeat polymorphisms of the CNR1 gene between the patient group and the control group. Conclusions Although our study revealed no significant association of the AAT-repeat polymorphism of the CNR1 gene with schizophrenia, it will serve as a good reference for future studies designed to examine the cannabinoid hypothesis of schizophrenia.

Keywords

References

  1. Karayiorgou M, Gogos JA. A turning point in schizophrenia genetics. Neuron 1997;19:967-979. https://doi.org/10.1016/S0896-6273(00)80390-6
  2. Ujike H, Morita Y. New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 2004;96:376-381. https://doi.org/10.1254/jphs.FMJ04003X4
  3. Sewell RA, Ranganathan M, D'Souza DC. Cannabinoids and psychosis. Int Rev Psychiatry 2009;21:152-162. https://doi.org/10.1080/09540260902782802
  4. Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Perez-Hernandez E, et al. (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 2006;256:437-441. https://doi.org/10.1007/s00406-006-0665-3
  5. Liskow B. Marihuana deterioration. JAMA 1970;214:1709.
  6. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananás L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006;31:2748-2757. https://doi.org/10.1038/sj.npp.1301197
  7. Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Geneenvironment interplay between cannabis and psychosis. Schizophr Bull 2008;34:1111-1121. https://doi.org/10.1093/schbul/sbn108
  8. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006;188:425-444. https://doi.org/10.1007/s00213-006-0508-y
  9. Gardner EL. Cannabinoid interaction with brain reward systems. The neurobiological basis of cannabinoid abuse. In: Murphy L, Bartke A, editors. Marijuana/Cannabinoids: Neurobiology and Neurophysiology. Boca Raton, FL: CRC Press;1992. p.275-335.
  10. Pazos MR, Nunez E, Benito C, Tolon RM, Romero J. Functional neuroanatomy of the endocannabinoid system. Pharmacol Biochem Behav 2005;81:239-247. https://doi.org/10.1016/j.pbb.2005.01.030
  11. Gardner EL. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 2005;81:263-284. https://doi.org/10.1016/j.pbb.2005.01.032
  12. Bossong MG, van Berckel BN, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759-766. https://doi.org/10.1038/npp.2008.138
  13. Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex 2007;17:175-191.
  14. Auclair N, Otani S, Soubrie P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. J Neurophysiol 2000;83:3287-3293. https://doi.org/10.1152/jn.2000.83.6.3287
  15. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564. https://doi.org/10.1038/346561a0
  16. Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A, et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 1997;43:1-8. https://doi.org/10.1006/geno.1997.4815
  17. Gadzicki D, Muller-Vahl K, Stuhrmann M. A frequent polymorphism in the coding exon of the human cannabinoid receptor (CNR1) gene. Mol Cell Probes 1999;13:321-323. https://doi.org/10.1006/mcpr.1999.0249
  18. Dawson E. Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiat Genet 1995;5:S50.
  19. Ponce G, Hoenicka J, Rubio G, Ampuero I, Jimenez-Arriero MA, Rodriguez-Jimenez R, et al. Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 2003;8:466-467. https://doi.org/10.1038/sj.mp.4001278
  20. Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, et al. Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 1997;2:161-168. https://doi.org/10.1038/sj.mp.4000247
  21. Li T, Liu X, Zhu ZH, Zhao J, Hu X, Ball DM, et al. No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. Mol Psychiatry 2000;5:128-130. https://doi.org/10.1038/sj.mp.4000670
  22. Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 2002;7:515-518. https://doi.org/10.1038/sj.mp.4001029
  23. Tsai SJ, Wang YC, Hong CJ. Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 2000;10:149-151. https://doi.org/10.1097/00041444-200010030-00008
  24. Chavarria-Siles I, Contreras-Rojas J, Hare E, Walss-Bass C, Quezada P, Dassori A, et al. Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 2008;147:279-284.
  25. Almeida B, Fernandes S, Abreu IA, Macedo-Ribeiro S. Trinucleotide repeats: a structural perspective. Front Neurol 2013;4:1-24.